Feb 18, 2025 08:00AM
Dec 3, 2024 11:02AM
Aug 14, 2024 08:01AM
Aug 14, 2024 08:00AM
Jun 20, 2024 08:00AM
Apr 24, 2024 08:09AM
Apr 24, 2024 08:08AM Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients
May 1, 2023 08:09AM
May 1, 2023 08:08AM
Apr 3, 2023 08:11AM
Apr 3, 2023 08:08AM
Feb 28, 2023 08:08AM
Feb 28, 2023 08:08AM
Feb 16, 2023 08:08AM Kiromic BioPharma (KRBP) CEO Issues Letter to Stockholders
Feb 16, 2023 08:08AM
Oct 6, 2022 08:09AM
Oct 6, 2022 08:08AM
Oct 2, 2022 09:00PM
Sep 26, 2022 09:00PM
Sep 21, 2022 09:00PM
Sep 16, 2022 09:00PM Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Carvana, Kiromic, Tuya, and LifeStance and Encourages Investors to Contact the Firm
Sep 11, 2022 09:00PM
Sep 6, 2022 09:28PM
Aug 31, 2022 09:00PM
Aug 26, 2022 09:00PM
Aug 21, 2022 09:00PM
Aug 15, 2022 09:00PM
Aug 10, 2022 09:00PM Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Carvana and Kiromic and Encourages Investors to Contact the Firm
Jul 7, 2022 08:25AM
Jul 7, 2022 08:18AM
Jun 21, 2022 08:17AM
Jun 7, 2022 07:05AM
Jun 7, 2022 07:05AM
May 11, 2022 06:58AM
May 11, 2022 06:58AM Kiromic BioPharma Announces Company Will Directly Submit Amended IND for Procel™ to the FDA in Second Half of 2022
Mar 11, 2022 04:03PM
Mar 11, 2022 04:02PM
Feb 3, 2022 08:02AM
Oct 11, 2021 08:04AM
Oct 11, 2021 08:02AM
Aug 13, 2021 03:32PM
Jul 16, 2021 02:55PM Kiromic BioPharma (KRBP) Provides Update on IND Filings on its Off-the-Shelf, Allogeneic CAR-T for Solid Tumors
Jul 16, 2021 02:53PM
Jun 7, 2021 08:11AM
Jun 7, 2021 08:07AM
May 24, 2021 07:55AM
May 24, 2021 07:55AM
May 17, 2021 07:59AM
May 17, 2021 07:58AM Kiromic Announces FDA IND Submission Forty-Five Days before the end of the Second Quarter: First-In-Human, Off-The-Shelf Chimeric PD1 Switch Receptor - Gamma Delta T-cell Therapy
Mar 31, 2021 12:32PM

322,953 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All